Evolving Therapies For Multiple Sclerosis

Elena Korniychuk, John M. Dempster, Eileen O'Connor, J. Steven Alexander, Roger E. Kelley, Meghan Kenner, Uma Menon, Vivek Misra, Romy Hoque, Eduardo Gonzalez-Toledo, Robert N. Schwendimann, Stacy Smith, Alireza Minagar

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


The introduction of immunomodulatory and immunosuppressive agents for treatment of multiple sclerosis (MS) has forever altered the natural course of this incurable and disabling neurodegenerative disorder. Despite early diagnosis of relapsing-remitting MS and early initiation of therapy, patients still experience breakthrough relapses and progression of their underlying MS pathology. The imperfect effectiveness, side effects, and toxicity of these agents, emphasize the necessity for development of more effective medications with less adverse events. This chapter presents readers with the most current information on the nature, mechanism(s) of action, and side effects of the most promising experimental agents currently under clinical trials. Some of the agents now at different stages of clinical trial have emerged as both safe and promising. The understanding of MS etiology will lead to the development of increasingly specific, safer, and effective treatments for MS by neuroscientists and neurologists.

Original languageEnglish (US)
Title of host publicationThe Neurobiology of Multiple Sclerosis
EditorsAlireza Minagar
Number of pages18
StatePublished - May 24 2007

Publication series

NameInternational Review of Neurobiology
ISSN (Print)0074-7742

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Evolving Therapies For Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this